$-0.40 EPS Expected for Retrophin, Inc. (RTRX)

July 13, 2018 - By Michele Cranor

Retrophin, Inc. (NASDAQ:RTRX) LogoInvestors sentiment increased to 1.24 in 2018 Q1. Its up 0.11, from 1.13 in 2017Q4. It increased, as 14 investors sold Retrophin, Inc. shares while 32 reduced holdings. 21 funds opened positions while 36 raised stakes. 39.72 million shares or 2.28% more from 38.84 million shares in 2017Q4 were reported.
Jacobs Levy Equity Inc has invested 0.01% in Retrophin, Inc. (NASDAQ:RTRX). Tiaa Cref Invest Limited Co accumulated 633,766 shares or 0.01% of the stock. Carroll has invested 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX). Quantbot Techs Limited Partnership owns 4,958 shares. Ameriprise stated it has 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX). Broadfin Capital Ltd Llc reported 1.18M shares or 4.11% of all its holdings. Emory University has invested 1.84% in Retrophin, Inc. (NASDAQ:RTRX). Rock Springs Capital Management Ltd Partnership has 400,000 shares. Virginia Retirement Et Al invested in 60,300 shares. Moreover, Lombard Odier Asset Mgmt (Usa) Corporation has 0.52% invested in Retrophin, Inc. (NASDAQ:RTRX). Geode Cap Ltd owns 368,083 shares. Deutsche Bankshares Ag, Germany-based fund reported 775,413 shares. Legal And General Group Incorporated Public Ltd Company holds 0% or 10,953 shares. First Mercantile Company stated it has 4,230 shares. Blackrock stated it has 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX).

Since February 14, 2018, it had 0 insider purchases, and 1 insider sale for $22,232 activity.

Analysts expect Retrophin, Inc. (NASDAQ:RTRX) to report $-0.40 EPS on August, 8.They anticipate $0.06 EPS change or 17.65 % from last quarter’s $-0.34 EPS. After having $-0.46 EPS previously, Retrophin, Inc.’s analysts see -13.04 % EPS growth. The stock increased 2.70% or $0.75 during the last trading session, reaching $28.54. About 217,775 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 70.38% since July 13, 2017 and is uptrending. It has outperformed by 57.81% the S&P500.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $1.14 billion. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

More news for Retrophin, Inc. (NASDAQ:RTRX) were recently published by: Globenewswire.com, which released: “Retrophin to Report Second Quarter 2018 Financial Results” on July 12, 2018. Nasdaq.com‘s article titled: “Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued US Patent” and published on June 14, 2018 is yet another important article.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.